News Headlines Article

Prostate cancer vaccine nabbed by Bristol-Myers Squibb for potential $1 billion
San Francisco Business Times

In its third Bay Area deal of the past two weeks, drug giant Bristol-Myers Squibb Co. will pay up to $975 million to license and sell an experimental prostate cancer vaccine under development by Bavarian Nordic.

Bristol-Myers Squibb (NYSE: BMY) last week closed on a potential $1.2 billion deal with San Carlos’ Flexus Biosciences Inc. It also struck a potential $339 million partnership with Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) of South San Francisco.